We’ve recently updated our valuation analysis.

Haemonetics Valuation

Is HAE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HAE?

Other financial metrics that can be useful for relative valuation.

HAE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.5x
Enterprise Value/EBITDA19.2x
PEG Ratio1.8x

Price to Earnings Ratio vs Peers

How does HAE's PE Ratio compare to its peers?

The above table shows the PE ratio for HAE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average72.2x
MMSI Merit Medical Systems
65.9x24.9%US$4.1b
BLCO Bausch + Lomb
89.1x29.1%US$5.2b
NEOG Neogen
96.1x70.6%US$3.5b
LNTH Lantheus Holdings
37.8x19.4%US$4.0b
HAE Haemonetics
49.5x27.4%US$4.3b

Price-To-Earnings vs Peers: HAE is good value based on its Price-To-Earnings Ratio (49.5x) compared to the peer average (72.2x).


Price to Earnings Ratio vs Industry

How does HAE's PE Ratio compare vs other companies in the US Medical Equipment Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a18.3%
n/an/an/a

Price-To-Earnings vs Industry: HAE is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the US Medical Equipment industry average (33x)


Price to Earnings Ratio vs Fair Ratio

What is HAE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HAE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio49.5x
Fair PE Ratio35.5x

Price-To-Earnings vs Fair Ratio: HAE is expensive based on its Price-To-Earnings Ratio (49.5x) compared to the estimated Fair Price-To-Earnings Ratio (35.5x).


Share Price vs Fair Value

What is the Fair Price of HAE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HAE ($84.13) is trading below our estimate of fair value ($139.94)

Significantly Below Fair Value: HAE is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HAE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$84.13
US$95.29
+13.3%
6.3%US$105.00US$88.00n/a7
Nov ’23US$83.96
US$86.57
+3.1%
3.8%US$90.00US$80.00n/a7
Oct ’23US$74.03
US$83.17
+12.3%
8.0%US$90.00US$74.00n/a6
Sep ’23US$74.42
US$83.17
+11.8%
8.0%US$90.00US$74.00n/a6
Aug ’23US$68.85
US$75.67
+9.9%
5.2%US$80.00US$70.00n/a6
Jul ’23US$67.32
US$75.67
+12.4%
5.2%US$80.00US$70.00n/a6
Jun ’23US$62.29
US$70.17
+12.6%
12.7%US$80.00US$60.00n/a6
May ’23US$50.67
US$72.29
+42.7%
9.7%US$80.00US$64.00n/a7
Apr ’23US$63.85
US$71.57
+12.1%
11.0%US$80.00US$60.00n/a7
Mar ’23US$57.52
US$70.86
+23.2%
10.3%US$80.00US$60.00n/a7
Feb ’23US$48.83
US$70.14
+43.6%
11.5%US$80.00US$59.00n/a7
Jan ’23US$53.04
US$73.13
+37.9%
11.2%US$86.00US$59.00n/a8
Dec ’22US$50.16
US$75.13
+49.8%
8.3%US$86.00US$67.00n/a8
Nov ’22US$70.78
US$79.25
+12.0%
8.6%US$90.00US$68.00US$83.968
Oct ’22US$72.00
US$79.25
+10.1%
8.6%US$90.00US$68.00US$74.038
Sep ’22US$63.82
US$79.25
+24.2%
8.6%US$90.00US$68.00US$74.428
Aug ’22US$60.79
US$80.29
+32.1%
8.0%US$90.00US$71.00US$68.857
Jul ’22US$67.73
US$80.29
+18.5%
8.0%US$90.00US$71.00US$67.327
Jun ’22US$57.02
US$81.17
+42.3%
8.1%US$90.00US$71.00US$62.296
May ’22US$67.26
US$117.43
+74.6%
30.1%US$185.00US$83.00US$50.677
Apr ’22US$112.04
US$155.71
+39.0%
8.5%US$185.00US$140.00US$63.857
Mar ’22US$129.40
US$155.71
+20.3%
8.5%US$185.00US$140.00US$57.527
Feb ’22US$115.00
US$143.50
+24.8%
8.4%US$170.00US$135.00US$48.836
Jan ’22US$118.75
US$126.71
+6.7%
10.7%US$145.00US$106.00US$53.047
Dec ’21US$112.55
US$118.29
+5.1%
11.7%US$145.00US$105.00US$50.167
Nov ’21US$101.09
US$114.83
+13.6%
12.8%US$145.00US$100.00US$70.786

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies